Step 3Correct for summation error in drug-responsive (no changes to five decimal places in matrix)

RemissionMildDrug-responsiveDrug-dependentDrug-refractorySurgeryPost-surgeryDeath
Remission0.941830.016110.011480.011430.012750.00641
Mild
Drug-responsive0.394800.434010.041870.032970.061090.03527
Drug-dependent0.075280.005490.889010.010020.013330.00688
Drug-refractory0.100630.010720.031420.749780.069560.03789
Surgery0.050670.014480.039080.031510.341750.52250
Post-surgery0.006260.002090.002410.002180.005220.98184
Death

From: 4, Assessment of cost-effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.